Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
